Neon Therapeutics Inc (NASDAQ:NTGN) saw unusually-strong trading volume on Monday . Approximately 1,056,675 shares were traded during trading, an increase of 612% from the previous session’s volume of 148,430 shares.The stock last traded at $4.62 and had previously closed at $4.32.
Several equities research analysts recently weighed in on NTGN shares. Morgan Stanley dropped their target price on Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating for the company in a report on Tuesday. Berenberg Bank dropped their target price on Lucara Diamond from C$1.60 to C$1.50 in a report on Wednesday, March 27th. Mizuho set a $21.00 target price on Neon Therapeutics and gave the company a “buy” rating in a report on Monday, July 1st. Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a report on Tuesday. Finally, HC Wainwright started coverage on Precision BioSciences in a report on Tuesday. They set a “buy” rating and a $21.00 target price for the company. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $16.00.
The stock’s 50-day moving average is $4.72. The firm has a market capitalization of $122.39 million and a price-to-earnings ratio of -0.78. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.30 and a current ratio of 7.30.
Neon Therapeutics (NASDAQ:NTGN) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.03). As a group, equities research analysts anticipate that Neon Therapeutics Inc will post -2.67 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTGN. Marshall Wace North America L.P. bought a new position in Neon Therapeutics during the 1st quarter valued at approximately $49,000. Harel Insurance Investments & Financial Services Ltd. raised its position in Neon Therapeutics by 100.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,000 shares of the company’s stock valued at $65,000 after purchasing an additional 5,000 shares during the last quarter. Rhumbline Advisers bought a new position in Neon Therapeutics during the 1st quarter valued at approximately $78,000. Bank of New York Mellon Corp raised its position in Neon Therapeutics by 17.6% during the 4th quarter. Bank of New York Mellon Corp now owns 19,427 shares of the company’s stock valued at $98,000 after purchasing an additional 2,905 shares during the last quarter. Finally, Bank of America Corp DE raised its position in Neon Therapeutics by 42.7% during the 4th quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock valued at $109,000 after purchasing an additional 6,493 shares during the last quarter. 69.57% of the stock is owned by institutional investors and hedge funds.
About Neon Therapeutics (NASDAQ:NTGN)
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
See Also: Why are trading ranges significant?
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.